Notes
If not all functional tests can be carried out in a reproducible manner in young children (3–6 years) but an ONL cannot be adequately detected, one can assume that functional residual tissue is present [9].
References
Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849–860. https://doi.org/10.1016/S0140-6736(17)31868-8
Bellingrath JS, Fischer MD (2015) Gene therapy as a treatment concept for inherited retinal diseases. Ophthalmologe 112:720–727. https://doi.org/10.1007/s00347-015-0121-8
Fischer MD (2016) On retinal gene therapy. Ophthalmologica 236:1–7. https://doi.org/10.1159/000445782
Thompson DA, Gyurus P, Fleischer LL, Bingham EL, McHenry CL, Apfelstedt-Sylla E, Zrenner E, Lorenz B, Richards JE, Jacobson SG, Sieving PA, Gal A (2000) Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci 41:4293–4299
Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, Pierce E, Sallum J, Larsen M, Stieger K, Preising M, Weleber R, Yang P, Place E, Liu E, Schaefer G, DiStefano-Pappas J, Elci OU, McCague S, Wellman JA, High KA, Reape KZ (2018) The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2018.09.024
Lorenz B, Gyurus P, Preising M, Bremser D, Gu S, Andrassi M, Gerth C, Gal A (2000) Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci 41:2735–2742
Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond TM (2008) A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. Invest Ophthalmol Vis Sci 49:5235–5242. https://doi.org/10.1167/iovs.07-1671
Narfstrom K, Vaegan KM, Bragadottir R, Rakoczy EP, Seeliger M (2005) Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 111:39–48. https://doi.org/10.1007/s10633-005-3159-0
Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J (2009) Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597–1605. https://doi.org/10.1016/S0140-6736(09)61836-5
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248. https://doi.org/10.1056/NEJMoa0802315
Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komaromy AM, Hauswirth WW, Aguirre GD (2013) Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.1218933110
Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239. https://doi.org/10.1056/NEJMoa0802268
Stieger K, Lorenz B (2018) Gentherapie bei degenerativen Erkrankungen der Netzhaut – ein Update. Z Prakt Augenheilkd 39:241–254
Nelles M, Stieger K, Preising MN, Kruse J, Lorenz B (2015) Shared decision-making, control preferences and psychological well-being in patients with RPE65 deficiency awaiting experimental gene therapy. Ophthalmic Res 54:96–102. https://doi.org/10.1159/000435887
Lorenz B, Wabbels B, Wegscheider E, Hamel CP, Drexler W, Preising MN (2004) Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65. Ophthalmology 111:1585–1594. https://doi.org/10.1016/j.ophtha.2004.01.033
Paunescu K, Wabbels B, Preising MN, Lorenz B (2005) Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol 243:417–426. https://doi.org/10.1007/s00417-004-1020-x
Robson AG, Nilsson J, Li S, Jalali S, Fulton AB, Tormene AP, Holder GE, Brodie SE (2018) ISCEV guide to visual electrodiagnostic procedures. Doc Ophthalmol 136:1–26. https://doi.org/10.1007/s10633-017-9621-y
Kumaran N, Pennesi ME, Yang P, Trzupek KM, Schlechter C, Moore AT, Weleber RG, Michaelides M (1993) Leber congenital amaurosis / early-onset severe retinal dystrophy overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) GeneReviews((R)). University of Washington, Seattle
Jacobson SG, Aleman TS, Cideciyan AV, Heon E, Golczak M, Beltran WA, Sumaroka A, Schwartz SB, Roman AJ, Windsor EA, Wilson JM, Aguirre GD, Stone EM, Palczewski K (2007) Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci U S A 104:15123–15128. https://doi.org/10.1073/pnas.0706367104
Lorenz B, Strohmayr E, Zahn S, Friedburg C, Kramer M, Preising M, Stieger K (2012) Chromatic pupillometry dissects function of the three different light-sensitive retinal cell populations in RPE65 deficiency. Invest Ophthalmol Vis Sci 53:5641–5652. https://doi.org/10.1167/iovs.12-9974
Roman AJ, Schwartz SB, Aleman TS, Cideciyan AV, Chico JD, Windsor EA, Gardner LM, Ying GS, Smilko EE, Maguire MG, Jacobson SG (2005) Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res 80:259–272. https://doi.org/10.1016/j.exer.2004.09.008
Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG (2007) Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas 28:N51–N56. https://doi.org/10.1088/0967-3334/28/8/N02
Jacobson SG, Aleman TS, Cideciyan AV, Roman AJ, Sumaroka A, Windsor EA, Schwartz SB, Heon E, Stone EM (2009) Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 50:2368–2375. https://doi.org/10.1167/iovs.08-2696
Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal A (1997) Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet 17:194–197. https://doi.org/10.1038/ng1097-194
Fischer MD, Hickey DG, Singh MS, MacLaren RE (2016) Evaluation of an optimized injection system for retinal gene therapy in human patients. Hum Gene Ther Methods 27:150–158. https://doi.org/10.1089/hgtb.2016.086
Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, Ueffing M, Biel M, Wissinger B, Bartz-Schmidt KU, Peters T, Fischer MD, RDCC (2017) Superior retinal gene transfer and biodistribution profile of subretinal versus Intravitreal delivery of AAV8 in nonhuman primates. Invest Ophthalmol Vis Sci 58:5792–5801. https://doi.org/10.1167/iovs.17-22473
Reichel FF, Peters T, Wilhelm B, Biel M, Ueffing M, Wissinger B, Bartz-Schmidt KU, Klein R, Michalakis S, Fischer MD, Consortium R‑C (2018) Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients. Invest Ophthalmol Vis Sci 59:1910–1915. https://doi.org/10.1167/iovs.17-22494
Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM (2012) AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4:120ra115. https://doi.org/10.1126/scitranslmed.3002865
Willett K, Bennett J (2013) Immunology of AAV-mediated gene transfer in the eye. Front Immunol 4:261. https://doi.org/10.3389/fimmu.2013.00261
Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, Banfi S, Surace EM, Sun J, Acerra C, Wright JF, Wellman J, High KA, Auricchio A, Bennett J, Simonelli F (2013) Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120:1283–1291. https://doi.org/10.1016/j.ophtha.2012.11.048
Ashtari M, Zhang H, Cook PA, Cyckowski LL, Shindler KS, Marshall KA, Aravand P, Vossough A, Gee JC, Maguire AM, Baker CI, Bennett J (2015) Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis. Sci Transl Med 7:296ra110. https://doi.org/10.1126/scitranslmed.aaa8791
Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, Hauswirth WW (2015) Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 372:1920–1926. https://doi.org/10.1056/NEJMoa1412965
Editorial board
Prof. Dr. med. Dominik Fischer, Tübingen, Germany (lead editor)
Prof. Dr. med. Bernd Bertram, Aachen, Germany
Prof. Dr. med. Ulrich, Kellner, Siegburg, Germany
Prof. Dr. med. Hansjuergen Agostini, Freiburg im Breisgau, Germany
Prof. Dr. med. Birgit Lorenz, Giessen, Germany
Dr. med. Philipp Herrmann, Bonn, Germany
Author information
Authors and Affiliations
Consortia
Ethics declarations
Conflict of interest
See Table 2 in the appendix.
This article does not contain any studies with human participants or animals performed by any of the authors.
The supplement containing this article is not sponsored by industry.
Appendix
Appendix
Rights and permissions
About this article
Cite this article
German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG)., German Retina Society e. V. (Retinologische Gesellschaft e. V., RG). & Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V., BVA). Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version. Ophthalmologe 117 (Suppl 1), 16–24 (2020). https://doi.org/10.1007/s00347-019-0906-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-019-0906-2